Fernand Labrie
Publications
Page 4 of 8, showing 50 records out of 368 total, starting on record 151, ending on 200
| Publication | Category | Year |
|---|---|---|
| 284. Labrie, F. (1984) Résultats exceptionnels d'un nouveau traitement du cancer de la prostate. Interface, 5: 23-25. | Prostate Cancer | 1984 |
| 283. Labrie, F. (1984) A new approach in the hormonal treatment of prostate cancer: complete instead of partial blockade of androgens. Int. J. Androl., 7: 1-4. | Prostate Cancer | 1984 |
| 304. Labrie, F. (1983) Luteinizing hormone-releasing hormone agonists and fertility regulation. The 9th Jennifer Hallam Memorial Lecture. J. Obst. Gynecol., 3: S37-S46. | Prostate Cancer | 1983 |
| 303. Labrie, F. (1983) A new therapy in prostatic cancer. Urology Times, August. | Prostate Cancer | 1983 |
| 321. Labrie, F. (1981) Changing the message from the brain. People, 8: 16-17. | Prostate Cancer | 1981 |
| 182. Labrie, C., Simard, J., Zhao, H., Bélanger, A., Pelletier, G., Labrie, F. (1989) Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology, 124: 2745-2754. | Prostate Cancer | 1989 |
| 181. Labrie, C., Simard, J., Marchetti, B., Pelletier, G., Zhao, H.F., Bélanger, A., Labrie, F. (1989) Conversion of precursor adrenal steroids into potent androgens in peripheral tissue, in: Labrie, F., Lee, F. et Dupont, A., eds: Early Stage Prostate Cancer: Diagnosis and Choice of Therapy, North Holland, Elsevier, ICS 841, pp 1-22. | Prostate Cancer | 1989 |
| 232. Labrie, C., Cusan, L., Plante, M., Lapointe, S., Labrie, F. (1987) Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer. J. Steroid Biochem., 28: 379-384. | Prostate Cancer | 1987 |
| 205. Labrie, C., Bélanger, A., Labrie, F. (1988) Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology, 123: 1412-1417. | Prostate Cancer | 1988 |
| 250. Harnois, C., Malenfant, M., Dupont, A., Labrie, F. (1986) Ocular toxicity of Anandron in patients treated for prostatic cancer. Br. J. Ophthalmol., 70: 471-473. | Prostate Cancer | 1986 |
| 351. Ferland, L., Labrie, F., Savary, M., Beaulieu, M., Coy, D.H., Coy, E.J., Schally, A.V. (1976) Inhibitory activity of analogues of luteinizing hormone-releasing hormone (LH-RH) in vitro and in vivo. Clin. Endocrinol. (Oxf.), 5: 279S-289S. | Prostate Cancer | 1976 |
| 282. Faure, N., Lemay, A., Tolis, G., Labrie, F., Bélanger, A., Fazekas, A.T.A. (1984) Buserelin therapy for prostatic carcinoma, in: Vickery, B.H., Nestor, J.J. et Hafez, E.S.E., eds: LHRH and its analogs: contraceptive and therapeutic applications, Boston, MTP Press, pp 337-349. | Prostate Cancer | 1984 |
| 320. Faure, N., Lemay, A., Bélanger, A., Labrie, F. (1981) Inhibition of androgen biosynthesis in the human male by chronic administration of [D-Ser(TBU)6]-des-Gly-NH210]LHRH ethylamide, in: Zatuchni, G.I., Shelton, J.D. et Sciarra, J.J., eds: LHRH peptides as female and male contraceptive, Philadelphia, Harper & Row, pp 307-320. | Prostate Cancer | 1981 |
| 313. Faure, N., Labrie, F., Lemay, A., Bélanger, A., Gourdeau, Y., Laroche, B., Robert, G. (1982) Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent LHRH agonist in adult men. Fertil. Steril., 37: 416-424. | Prostate Cancer | 1982 |
| 312. Faure, N., Labrie, F., Belanger, A., Lemay, A., Raynaud, J.P., Von der Ohe, M., Fazekas, A.T. (1982) Sensitivity of luteinizing hormone and gonadal steroid responses to single intranasal administration of an LHRH agonist (HOE-766) in young normal adult men. J. Endocrinol. Invest., 5: 355-360. | Prostate Cancer | 1982 |
| 74. Eeles, R.A., Durocher, F., Edwards, S., Teare, D., Badzioch, M., Hamoudi, R., Gill, S., Biggs, P., Dearnaley, D., Ardern-Jones, A., Dowe, A., Shearer, R., McLennan, D.L., Norman, R.L., Ghadirian, P., Aprikian, A., Ford, D., Amos, C., King, T.M., The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators, Labrie, F., Simard, J., Narod, S.A., Easton, D., Foulkes, W.D. (1998) Linkage analysis of chromosome 1q markers in 136 prostate cancer families. Am. J. Hum. Genet, 62: 653-658. | Prostate Cancer | 1998 |
| 203. Dupont, A., Labrie, F., Giguere, M., Borsanyi, J.-P., Lacourcière, Y., Bergeron, N., Cusan, L., Bélanger, A., Emond, J. (1988) Combination therapy with Flutamide and [D-Trp6]LHRH ethylamide for stage C prostatic carcinoma. Eur. J. Cancer Oncol., 24: 659-666. | Prostate Cancer | 1988 |
| 204. Dupont, A., Labrie, F., Giguère, M., Borsanyi, J.-P., Lacourcière, Y., Bélanger, A., Lachance, R., Emond, J., Monfette, G. (1988) Combination therapy with Flutamide and castration (orchiectomy or LHRH agonist) in untreated patients with advanced prostate cancer, in: Höffken, K., ed. LHRH agonists in Oncology. Symposium on GnRH Analogues, Essen, pp 60-71. | Prostate Cancer | 1988 |
| 249. Dubé, D., Poyet, P., Pelletier, G., Labrie, F. (1986) Radioautographic localization of ?-adrenergic receptors in the rat ventral prostate. J. Androl., 7: 169-174. | Prostate Cancer | 1986 |
| 202. Dubé, D., Pelletier, G., Labrie, F. (1988) The luteinizing hormone-releasing hormone (LHRH) agonist, [D-Trp6-des-Gly-NH2(10)]-LHRH ethylamide has no direct effect on spermatogenesis in the rat. Biol. Reprod., 38: 1165-1170. | Prostate Cancer | 1988 |
| 231. Dubé, D., Pelletier, G., Labrie, F. (1987) Morphological studies of the canine pituitary LH cells after long-term treatment with the LHRH agonist [D-Trp6]LHRH ethylamide. Endocrinology, 120: 589-594. | Prostate Cancer | 1987 |
| 230. Dubé, D., Assaf, A., Pelletier, G., Labrie, F. (1987) Morphological study of the effects of an GnRH agonist on the canine testis after 4 months of treatment and recovery. Acta Endocrinol. (Copenh.), 116: 413-417. | Prostate Cancer | 1987 |
| 339. Cusan, L., Auclair, C., Bélanger, A., Ferland, L., Kelly, P.A., Séguin, C., Labrie, F. (1979) Inhibitory effects of long-term treatment with an LHRH agonist on the pituitary-gonadal axis in male and female rats. Endocrinology, 104: 1369-1376. | Prostate Cancer | 1979 |
| 350. Coy, D.H., Labrie, F., Savary, M., Coy, E.J., Schally, A.V. (1976) Antagonistic activity of analogs of luteinizing hormone-releasing hormone (LHRH) in vitro. Mol. Cell. Endocrinol., 5: 201-208. | Prostate Cancer | 1976 |
| 73. Chen, C., Li, X., Singh, S.M., Labrie, F. (1998) Activity of 17beta-(N-alkyl/arylformamido)- and 17beta-[(N-alkyl/aryl) alkyl/arylamido]-4-methyl-4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors in the hamster flank organ and ear. J. Invest. Dermatol., 111: 273-278. | Prostate Cancer | 1998 |
| 311. Carmichael, R., Bélanger, A., Caron, S., Labrie, F., Sairam, M.R. (1982) Comparative effects of LHRH agonist and ovine LH administration on testicular steroidogenesis in intact adult rat. Steroids, 40: 641-649. | Prostate Cancer | 1982 |
| 1. Bydal, P., Luu-The, V., Labrie, F., Poirier, D. (2009) Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: Chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities. Eur J Med Chem.44:632-644. | Prostate Cancer | 2009 |
| 229. Brochu, M., Bélanger, A., Dupont, A., Cusan, L., Labrie, F. (1987) Effects of Flutamide and aminoglutethimide on plasma 5?-reduced steroid glucuronide concentrations in castrated patients with cancer of the prostate. J. Steroid Biochem., 28: 619-622. | Prostate Cancer | 1987 |
| 281. Bélanger, A., Tremblay, Y., Lacoste, D., Giasson, M., Dupont, A., Labrie, F. (1984) The dog, a good model for the study of LHRH agonists as blockers of androgen secretion and potential contraceptives, in: Labrie, F., Bélanger, A. et Dupont, A., eds: Proceedings of the International Symposium on LHRH and its Analogues: Basic and Clinical Aspects, New York, Excerpta Medica, pp 141-155. | Prostate Cancer | 1984 |
| 302. Bélanger, A., Labrie, F., Séguin, C., Cusan, L., Carmichael, R., Caron, S. (1983) Inhibition of testicular delta 4-androgen secretion in the rat by treatment with luteinizing hormone-releasing hormone, in: Negro-Vilar, A., ed. Male Reproduction and Fertility, New York, Raven Press, pp 127-139. | Prostate Cancer | 1983 |
| 333. Belanger, A., Labrie, F., Lemay, A., Caron, S., Raynaud, J.P. (1980) Inhibitory effects of a single intranasal administration of [D-Ser(TBU)6, des-Gly -NH210]LHRH ethylamide, a potent LHRH agonist, on serum steroid levels in normal adult men. J. Steroid Biochem., 13: 123-126. | Prostate Cancer | 1980 |
| 201. Belanger, A., Labrie, F., Dupont, A., Brochu, M., Cusan, L. (1988) Endocrine effects of combined treatment with an LHRH agonist in association with Flutamide in metastatic prostatic carcinoma. Clin. Invest. Med., 11: 321-326. | Prostate Cancer | 1988 |
| 200. Bélanger, A., Giasson, M., Cliche, J., Dupont, A., Labrie, F. (1988) Plasma levels of hydroxy-flutamide in patients with prostatic cancer receiving the combined hormonal therapy: an LHRH agonist and flutamide. Prostate, 12: 79-84. | Prostate Cancer | 1988 |
| 280. Bélanger, A., Dupont, A., Labrie, F. (1984) Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer. J. Clin. Endocrinol. Metab., 59: 422-426. | Prostate Cancer | 1984 |
| 332. Bélanger, A., Cusan, L., Séguin, C., Caron, S., Labrie, F. (1980) Inhibition de la stéroïdogénèse testiculaire chez le rat par traitement avec un agoniste de la LHRH. Union Med. Can., 109: 489-494. | Prostate Cancer | 1980 |
| 331. Bélanger, A., Cusan, L., Auclair, C., Séguin, C., Caron, S., Labrie, F. (1980) Effect of an LHRH agonist and hCG on testicular steroidogenesis in the adult rat. Biol. Reprod., 22: 1094-1101. | Prostate Cancer | 1980 |
| 319. Bélanger, A., Caron, S., Cusan, L., Séguin, C., Auclair, C., Labrie, F. (1981) Inhibition of testicular androgen biosynthesis by treatment with LHRH agonists, in: McKerns, K.W., ed. Reproductive Processes and Contraception. International Society for Biochemical Endocrinology, New York, Plenum Press, pp 471-491. | Prostate Cancer | 1981 |
| 338. Bélanger, A., Auclair, C., Séguin, C., Kelly, P.A., Labrie, F. (1979) Down-regulation of testicular androgen biosynthesis and LH receptor levels by an LHRH agonist: role of prolactin. Mol. Cell. Endocrinol., 13: 47-53. | Prostate Cancer | 1979 |
| 318. Bélanger, A., Auclair, C., Séguin, C., Caron, S., Labrie, F. (1981) Prolactin stimulation of testicular steroid biosynthesis in the male rat. J. Androl., 2: 80-86. | Prostate Cancer | 1981 |
| 330. Bélanger, A., Auclair, C., Ferland, L., Caron, S., Labrie, F. (1980) Time-course of the effect of treatment with a potent LHRH agonist on testicular steroidogenesis and gonadotropin receptor levels in the adult rat. J. Steroid Biochem., 13: 191-196. | Prostate Cancer | 1980 |
| 199. Bégin, D., Luthy, I.A., Labrie, F. (1988) Adrenal precursor C19 steroids are potent stimulators of growth of androgen-sensitive mouse mammary carcinoma Shionogi cells in vitro. Mol. Cell. Endocrinol., 58: 213-219. | Prostate Cancer | 1988 |
| 347. Auclair, C., Kelly, P.A., Labrie, F., Coy, D.H., Schally, A.V. (1977) Inhibition of testicular LH/hCG receptor level by treatment with a potent LHRH agonist or hCG. Biochem. Biophys. Res. Commun., 76: 855-862. | Prostate Cancer | 1977 |
| 346. Auclair, C., Kelly, P.A., Coy, D.H., Schally, A.V., Labrie, F. (1977) Potent inhibitory activity of [D-Leu6, des-Gly-NH2 10]ethylamide on LH/hCG and PRL testicular receptor levels in the rat. Endocrinology, 101: 1890-1893. | Prostate Cancer | 1977 |
| 343. Auclair, C., Ferland, L., Cusan, L., Kelly, P.A., Labrie, F., Azadian-Boulanger, G., Raynaud, J.P. (1978) Effet inhibiteur de la LHRH sur les récepteurs de la LH dans le testicule chez le rat. C.R. Acad. Sci. Hebd. Seances Acad. Sci. D, 286: 1305-1307. | Prostate Cancer | 1978 |
| 342. Auclair, C., Cusan, L., Kledzik, G.S., Ferland, L., Kelly, P.A., Labrie, F. (1978) Inhibition de fonctions gonadiques par la LHRH et ses agonistes chez le rat mâle et femelle. Union Med. Can., 107: 356-364. | Prostate Cancer | 1978 |
| 349. Asselin, J., Labrie, F., Gourdeau, Y., Bonne, C., Raynaud, J.P. (1976) Binding of [3H]methyltrienolone (Rl88l) in rat prostate and human benign prostatic hypertrophy (BPH). Steroids, 28: 449-459. | Prostate Cancer | 1976 |
| 55. Xu, J., The International Consortium for Prostate Cancer Genetics. (2000) Combined Analysis of Hereditary Prostate Cancer Linkage to 1q24-25: Results from 772 Hereditary Prostate Cancer Families from the International Consortium for Prostate Cancer Genetics. Am J Hum Genet., 66: 945-57. | Prostate Cancer | 2000 |
| 14. Vandenput, L., Labrie, F., Mellström, D., Swanson, C., Knutsson, T., Peeker, R., Ljunggren, O., Orwoll, E., Eriksson, A.L., Johnell, O., Damber, J.E., Ohlsson, C. (2007) Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. J. of Bone and Mineral Research: The Official Journal of the American Soc. for Bone and Mineral Research, 22: 220-7. | Prostate Cancer | 2007 |
| 107. van der Kwast, T.H., Tetu, B., Fradet, Y., Dupont, A., Gomez, J., Cusan, L., Diamond, P., Labrie, F. (1996) Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy. Prostate, 28: 227-231. | Prostate Cancer | 1996 |
| 106. Vaillancourt, L., Têtu, B., Fradet, Y., Dupont, A., Gomez, J., Cusan, L., Suburu, R.E., Diamond, P., Candas, B., Labrie, F. (1996). Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma: a randomized study. Am. J. Surg. Pathol., 20: 86-93. | Prostate Cancer | 1996 |